[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@stellanewslife Avatar @stellanewslife STELLANEWS.LIFE

STELLANEWS.LIFE posts on X about $4523t, japan, egypt, products the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks XX% countries XX% finance XX% currencies XXX%

Social topic influence $4523t #14, japan 5%, egypt #1097, products 5%, derivatives #199, longterm 2.5%, $3132t 2.5%, cps 2.5%, $4507t 2.5%, business XXX%

Top Social Posts

Top posts by engagements in the last XX hours

"Alexion reports positive Phase X results for gefurulimab in gMG highlights self-administered SC delivery at AANEM/MGFA Alexion reports Phase X success for gefurulimab in gMG: self-injectable C5 inhibitor meets endpoints at AANEM/MGFA #Alexion #AstraZeneca #gefurulimab #gMG #MyastheniaGravis #C5inhibitor #SelfInjection #Autoinjector #PrefilledSyringe #MGFA #AANEM2025 #Phase3Trial #MGADL #Ultomiris #Soliris"
X Link 2025-11-04T01:09Z XXX followers, XXX engagements

"Lecanemab May Delay Alzheimers Progression by Up to XXX Years CTAD 2025 At CTAD 2025 Eisai and Biogen presented new long-term analyses showing that continuous lecanemab (Leqembi) treatment could delay progression from MCI to moderate Alzheimers disease by up to XXX years particularly in amyloid-low patients. 💡 Key Findings: MCI mild AD: delay XXX years (up to XXX years in amyloid-low group) MCI moderate AD: delay XXX years (up to XXX years in amyloid-low group) Subcutaneous lecanemab (SC-AI) showed pharmacokinetic equivalence to IV dosing (104%) Lower infusion reactions improved convenience"
X Link 2025-12-08T01:06Z XXX followers, XX engagements

"CASGEVY Achieves Primary Endpoints in All Children (Ages 511) ASH 2025 At the American Society of Hematology (ASH) 2025 Vertex reported Phase X data showing that exagamglogene autotemcel (CASGEVY) met all primary endpoints in children aged XXX with severe sickle cell disease (SCD) or transfusion-dependent -thalassemia (TDT). 🔹 Key Results: SCD: All evaluable patients (4/4) remained VOC-free XX months TDT: All evaluable patients (6/6) achieved XX months transfusion independence 12-year cohort: XXX VOC-free (SCD) XXXX transfusion independence (TDT) sustained X years Safety profile consistent"
X Link 2025-12-08T01:08Z XXX followers, XX engagements

"Siemens and Macnica strengthen OT collaboration for CPS integration to accelerate Japans manufacturing DX #Siemens #Macnica #CPS #ManufacturingDX #IndustrialEdge #DigitalTwin #SmartFactory #IndustrialAI #PredictiveMaintenance"
X Link 2025-11-12T02:36Z XXX followers, XX engagements

"Shionogi completes succession of Japan Tobaccos pharmaceutical business and acquisition of Akros Pharma #Shionogi #BusinessSuccession #JTPharma #AkrosPharma #PharmaIndustry #CorporateReorganization"
X Link 2025-12-02T06:03Z XXX followers, XX engagements

"Grifols hosts Free to be you forum to advance employment inclusion for people with disabilities #DisabilityInclusion #Grifols #EmploymentEquity #DiversityAndInclusion #WorkplaceInclusion #FreeToBeYou"
X Link 2025-12-02T06:04Z XXX followers, XXX engagements

"EMA validates Type II variation application for PADCEV + pembrolizumab in muscle-invasive bladder cancer (MIBC) #BladderCancer #PADCEV #KEYTRUDA #Astellas #Pembrolizumab #MIBC #EV303 #EMA"
X Link 2025-12-02T11:38Z XXX followers, XX engagements

"Novo Nordisk's amycretin achieves HbA1c and weight reduction in phase X trial #Amycretin #Type2Diabetes #GLP1 #Amylin #NovoNordisk #HbA1c #Obesity #Phase2"
X Link 2025-12-02T11:52Z XXX followers, XX engagements

"Novo Nordisk submits sNDA for 7.2mg semaglutide after STEP UP trial shows XXXX% weight loss #Semaglutide #Wegovy #ObesityTreatment #GLP1 #STEPUP #NovoNordisk #WeightLoss #FDA"
X Link 2025-12-02T11:54Z XXX followers, XX engagements

"Lecanemab Demonstrates Pharmacologic Effects on A Protofibrils in CSF CTAD 2025 At CTAD 2025 Eisai and Biogen presented new analyses from the Clarity AD Phase X trial showing that lecanemab (Leqembi) engages its target A protofibrils in cerebrospinal fluid. 🧠 Key findings (CSF subcohort n=410): Total A protofibrils XX at XX months (vs +19 in placebo p=0.0126) Positive correlations with tau/neuronal biomarkers seen in placebo absent in lecanemab group Suggests reduced neurotoxic impact of protofibrils via target engagement These data support lecanemabs dual mechanismbinding both toxic"
X Link 2025-12-08T01:03Z XXX followers, XX engagements

"Egypt Achieves Self-Sufficiency in Plasma-Derived Medicines Grifols Announces Milestone Egypt has become the 6th country worldwide to achieve national self-sufficiency in plasma-derived products including immunoglobulins albumin and coagulation factors through Grifols Egypt for Plasma Derivatives (GEPD). 💡 Key Highlights: 55M GDP contribution in 2025 rising to 272M+ annually by 2030 1200 direct jobs over 14000 indirect jobs and 180000+ expected new jobs by 2029 Strengthened healthcare independence and regional supply stability across Africa & the Middle East This marks a major step for"
X Link 2025-12-08T01:09Z XXX followers, XX engagements

"Bayer Initiates Phase IIa ASSESS Trial of BAY 3401016 in Alport Syndrome Bayer has launched a Phase IIa study evaluating BAY 3401016 a monoclonal antibody targeting Semaphorin 3A (Sema3A) in patients with Alport Syndrome a rare inherited kidney disease. 🔹 Key Highlights Randomized double-blind placebo-controlled design Evaluates kidney function preservation and safety Received FDA Fast Track and Orphan Drug Designations The study represents a novel approach in nephrology aiming to slow disease progression through Sema3A inhibition a potential first-in-class mechanism. 🔗 Read more: #Bayer"
X Link 2025-12-08T01:36Z XXX followers, XX engagements

"Japan approves BRAFTOVI combo as first-line treatment for BRAFV600E-mutant metastatic CRC Ono Pharmaceutical has received approval in Japan to expand the indication of BRAFTOVI (encorafenib) for first-line use in combination with cetuximab and FOLFOX in unresectable advanced or recurrent colorectal cancer (CRC) with BRAFV600E mutation. The global phase X BREAKWATER study showed significant improvements in both objective response rate (60.9% vs. 40.0%) and PFS (12.8 vs. XXX months) vs. chemotherapy alone. This marks a potential shift in first-line standards for this poor-prognosis subgroup. 🔗"
X Link 2025-11-24T21:10Z XXX followers, XX engagements

"Sumitomo Pharma Donates X Million to Support Victims of the Oita-Saganoseki Fire Sumitomo Pharma Co. Ltd. announced a donation of X million (500000 each to Oita Prefecture and Oita City) to support recovery efforts following the large-scale fire in Saganoseki Oita City on November XX 2025. The company expressed its deepest sympathies to those affected and hopes for the swift recovery of the local community. 🔗 Full release: #SumitomoPharma #CorporateSocialResponsibility #Oita #Saganoseki #DisasterRelief #CommunitySupport #PharmaIndustry"
X Link 2025-12-06T18:12Z XXX followers, XX engagements

"Aflibercept XX mg/mL Bayer Listed in Japans NHI Drug Price List The aflibercept intravitreal injection kit XX mg/mL Bayer has been officially added to Japans National Health Insurance (NHI) price list as of December X 2025. 🔹 The product is a bioauthorized follow-on biologic with the same active ingredient excipients and manufacturing process as Eylea. 🔹 It is approved for four retinal diseases including age-related macular degeneration and diabetic macular edema. 🔹 Bayer LifeScience holds the manufacturing approval while Santen Pharmaceutical will handle marketing and distribution in"
X Link 2025-12-08T00:57Z XXX followers, XX engagements

"Eisais Anti-Tau Antibody Etalanetug Significantly Lowers Novel Biomarker eMTBR-tau243 At CTAD 2025 Eisai reported Phase Ib/II results showing that etalanetug (E2814) markedly reduced eMTBR-tau243 a new biomarker linked to tau pathology in both CSF and blood of participants with dominantly inherited Alzheimers disease. 🔬 Key data: CSF eMTBR-tau243 XX at X months XX at X months Blood eMTBR-tau243 XX at X months XX at X months Supports the mechanism of inhibiting tau seeding and spread Etalanetug is being tested with lecanemab (Leqembi) in the Tau NexGen Phase II/III trial and has received FDA"
X Link 2025-12-08T01:01Z XXX followers, XX engagements

"Egypt Achieves Self-Sufficiency in Plasma-Derived Medicines Grifols Announces Milestone Egypt has become the 6th country worldwide to achieve national self-sufficiency in plasma-derived products including immunoglobulins albumin and coagulation factors through Grifols Egypt for Plasma Derivatives (GEPD). 💡 Key Highlights: 55M GDP contribution in 2025 rising to 272M+ annually by 2030 1200 direct jobs over 14000 indirect jobs and 180000+ expected new jobs by 2029 Strengthened healthcare independence and regional supply stability across Africa & the Middle East This marks a major step for"
X Link 2025-12-08T01:11Z XXX followers, XX engagements

"Bayer Launches Phase III SUNFLOWER Trial for Nonatypical Endometrial Hyperplasia Bayer has initiated a global Phase III trial evaluating a XX mg levonorgestrel-releasing intrauterine system (LNG-IUS) versus oral progestin in women with nonatypical endometrial hyperplasia (NAEH). 🌼 Key Details XXX participants across XX sites in X countries XXX years of treatment and histologic assessment Aims to establish a nonsurgical medical therapy where no approved drug currently exists This study may expand the therapeutic use of Mirena already well known for contraception and heavy menstrual bleeding."
X Link 2025-12-08T01:29Z XXX followers, XX engagements

"Bayer Presents Pediatric Data for Low-Dose MRI Contrast Agent Gadoquatrane at RSNA 2025 The QUANTI Pediatric study evaluated gadoquatrane at XXXX mmol Gd/kg in children (018 years). Results showed pharmacokinetics and safety comparable to adults despite a XX% lower dose than standard macrocyclic GBCAs. 🔹 Highlights XX pediatric participants No new safety signals Supports global regulatory submissions (Japan U.S. EU China) The findings underscore gadoquatranes potential as a next-generation low-dose MRI contrast agent for pediatric imaging. 🔗 Full article: #Bayer #MRI #Gadoquatrane #RSNA2025"
X Link 2025-12-08T01:34Z XXX followers, XX engagements

"AstraZenecas Baxdrostat Accepted for FDA Priority Review First-in-Class Aldosterone Synthase Inhibitor for Resistant Hypertension The U.S. FDA has accepted AstraZenecas NDA for baxdrostat with Priority Review for adults with hard-to-control hypertension. 🔹 Key Highlights Based on Phase X BaxHTN trial (n=796) Mean seated SBP reduction: XXXX mmHg (9.8 mmHg vs placebo p0.001) Consistent effects across resistant and uncontrolled hypertension subgroups Favorable safety profile with no new safety signals If approved baxdrostat would become the first aldosterone synthase inhibitor to reach the"
X Link 2025-12-08T01:46Z XXX followers, XX engagements

"AstraZeneca Showcases Record-Breaking Haematology and Cell Therapy Data at ASH 2025 At #ASH2025 AstraZeneca will present its largest-ever haematology portfolio XX abstracts including XX oral presentations spanning blood cancers rare blood disorders and cell therapy. 🔹 Highlights surovatamig (CD19CD3 T-cell engager): early data in FL B-ALL DLBCL AZD0120 (BCMACD19 CAR-T): promising results in multiple myeloma Calquence: long-term MCL & CLL analyses Ultomiris: new data in paediatric HSCT-TMA These presentations underscore AstraZenecas expanding leadership in next-generation immunotherapies and"
X Link 2025-12-08T01:48Z XXX followers, XX engagements